Burcon Nutrascience Achieves Commercial Production Milestone in Texas, Strengthening Plant-Based Protein Market

Burcon Nutrascience Corporation has reached a critical milestone by scaling up the commercial production of its pea protein isolate at its Galesburg facility, a development that significantly enhances its market entry strategy. This achievement, realized in under 90 days, enables Burcon to address increasing customer demand and seize revenue opportunities in a market with an estimated total addressable market (TAM) of between US$215M and US$392M. This move is pivotal for the company as it seeks to establish a stronger foothold in the competitive plant-based protein sector.

In a strategic maneuver to bolster its financial standing, Burcon has initiated a share consolidation program at a 20:1 ratio, effective June 11, 2025. This decision reflects the company's dedication to optimizing its capital structure and ensuring long-term sustainability. Furthermore, Burcon's collaboration with ProMan, announced in the third quarter of 2025, represents a significant advancement. This partnership involves ProMan acquiring and leasing a protein production facility to Burcon, allowing the latter to adopt a capital-light strategy while retaining complete control over its plant-based protein production. With production slated to begin within 90 days, Burcon is confident in achieving its revenue goals, projecting first-year sales between $1M and $3M, and surpassing $10M in the second year, with profitability and positive cash flows expected by FY26.

Burcon's efforts to commercialize its products have also progressed, including partnerships with Puratos to investigate new uses for canola protein and the introduction of next-generation Peazazz® pea protein and Puratein® canola protein for egg replacement applications. The launch of Solatein™ sunflower protein isolate further expands Burcon's diverse product lineup. Financially, the company reported $0.06M in revenues from protein isolate sales and contract research services in 3Q25, an improvement from no revenues in the same quarter the previous year. Despite a net loss of $1.8M, or $0.01 per share, this marks an enhancement from a net loss of $2.0M, or $0.02 per share, in the corresponding period last year. With a pro-forma cash balance of around $10.0M after a successful rights offering, Burcon is well-equipped to maintain its operations and pursue growth in the expanding plant-based protein industry.